Publication:
Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002)

dc.contributor.authorsGultekin, Melis; Esen, Caglayan Selenge Beduk; Balci, Beril; Alanyali, Senem; Yildirim, Berna Akkus; Guler, Ozan Cem; Sari, Sezin Yuce; Ergen, Sefika Arzu; Sahinler, Ismet; Cetin, Ilknur Alsan; Onal, Cem; Yildiz, Ferah; Ozsaran, Zeynep
dc.date.accessioned2022-03-12T22:58:37Z
dc.date.accessioned2026-01-10T19:28:43Z
dc.date.available2022-03-12T22:58:37Z
dc.date.issued2021
dc.description.abstractObjective There are a limited number of studies supporting vaginal brachytherapy boost to external beam radiotherapy in the adjuvant treatment of cervical cancer. The aim of this study was to assess the impact of the addition of vaginal brachytherapy boost to adjuvant external beam radiotherapy on oncological outcomes and toxicity in patients with cervical cancer. Methods Patients treated with post-operative external beam radiotherapy +/- chemotherapy +/- vaginal brachytherapy between January 2001 and January 2019 were retrospectively evaluated. The treatment outcomes and prognostic factors were analyzed in patients treated with external beam radiotherapy with or without vaginal brachytherapy. Results A total of 480 patients were included in the analysis. The median age was 51 years (range 42-60). At least two intermediate risk factors were observed in 51% of patients, while 49% had at least one high-risk factor. The patients in the external beam radiotherapy + vaginal brachytherapy group had worse prognostic factors than the external beam radiotherapy alone group. With a median follow-up time of 56 months (range 33-90), the 5-year overall survival rate was 82%. There was no difference in 5-year overall survival (87% vs 79%, p=0.11), recurrence-free survival (74% vs 71%, p=0.49), local recurrence-free survival (78% vs 76%, p=0.16), and distant metastasis-free survival (85% vs 76%, p=0.09) rates between treatment groups. There was no benefit of addition of vaginal brachytherapy to external beam radiotherapy in patients with positive surgical margins. In multivariate analysis, stage (overall survival and local recurrence-free survival), tumor histology (recurrence-free survival, local recurrence-free survival and distant metastasis-free survival), parametrial invasion (recurrence-free survival and distant metastasis-free survival), lymphovascular space invasion (recurrence-free survival), and lymph node metastasis (distant metastasis-free survival) were found as negative prognostic factors. Conclusion Adding vaginal brachytherapy boost to external beam radiotherapy did not provide any benefit in local control or survival in patients with cervical cancer.
dc.identifier.doi10.1136/ijgc-2020-001733
dc.identifier.eissn1525-1438
dc.identifier.issn1048-891X
dc.identifier.pubmed32998860
dc.identifier.urihttps://hdl.handle.net/11424/237212
dc.identifier.wosWOS:000616726100005
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUP
dc.relation.ispartofINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectradiotherapy
dc.subjectbrachytherapy
dc.subjectuterine cervical neoplasms
dc.subjectRADICAL HYSTERECTOMY
dc.subjectENDOMETRIAL CARCINOMA
dc.subjectCONSENSUS GUIDELINES
dc.subjectRANDOMIZED-TRIAL
dc.subjectSTAGE
dc.subjectTHERAPY
dc.subjectIRRADIATION
dc.subjectSURGERY
dc.subjectCHEMOTHERAPY
dc.subjectCRITERIA
dc.titleRole of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002)
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage193
oaire.citation.issue2
oaire.citation.startPage185
oaire.citation.titleINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
oaire.citation.volume31

Files